Bank of America CEO Brian Moynihan recently highlighted the substantial financial impact that GLP-1 medications are having on the company’s health care costs. In comments reported by CNBC, Moynihan explained that these drugs, primarily used for treating type 2 diabetes and obesity, have driven up the bank’s overall medical expenses by roughly 15 percent in recent quarters. The revelation underscores a broader trend affecting major employers across the United States as employee demand for medications such as Ozempic, Wegovy, Mounjaro, and Zepbound continues to climb.
The surge in GLP-1 prescriptions stems from their proven effectiveness in promoting significant weight loss and improving blood sugar control. Clinical studies show that many patients lose 15 to 20 percent of their body weight within the first year of consistent use. For employers like Bank of America, which self-insures its workforce of more than 200,000 people, this popularity translates directly into higher pharmacy benefit payouts. Moynihan noted that the bank has seen a marked increase in both the number of employees requesting these drugs and the duration for which they remain on treatment. Many participants appear committed to long-term use, viewing the medications as a sustainable approach to managing chronic conditions rather than a temporary fix.
This development arrives at a time when corporate health care spending already faces pressure from rising premiums, an aging workforce, and post-pandemic effects on employee wellness. Bank of America’s experience mirrors reports from other large organizations, including Walmart, General Motors, and several major health systems that have publicly discussed similar cost increases. The medications typically carry list prices exceeding $1,000 per month, although negotiated discounts and rebates can reduce the net expense for plan sponsors. Even with those concessions, the volume of claims has pushed total expenditures higher than many benefit managers anticipated when coverage policies were first expanded.
Analysts estimate that GLP-1 drugs could add billions of dollars in annual costs to the U.S. health care system if current adoption rates persist. For context, the American Diabetes Association and the American Heart Association have broadened recommendations for these therapies beyond diabetes management to include cardiovascular risk reduction and obesity treatment. Those endorsements have encouraged physicians to prescribe them more readily, while direct-to-consumer advertising and widespread media coverage have heightened public awareness. Employees at companies with generous pharmacy benefits often face relatively low out-of-pocket costs, which further accelerates uptake.
Bank of America has responded to the trend by refining its pharmacy management strategies without eliminating access. The company continues to cover the drugs for employees who meet clinical criteria, but it has introduced additional oversight measures such as prior authorization requirements and step therapy protocols. These steps encourage the use of lower-cost alternatives when appropriate and ensure that prescriptions align with evidence-based guidelines. Moynihan emphasized that the bank remains committed to supporting employee health while exercising prudent financial stewardship. He indicated that ongoing negotiations with pharmacy benefit managers and drug manufacturers could help moderate future price increases.
The conversation around GLP-1 costs also raises questions about long-term value. Proponents argue that successful weight management can reduce other expensive medical claims over time. Obesity contributes to higher rates of heart disease, stroke, joint problems, and certain cancers, all of which generate substantial treatment expenses. If employees achieve lasting improvements in metabolic health, the theory suggests that downstream savings in hospital visits, procedures, and chronic disease management could eventually offset some of the upfront drug costs. Early data from select employers show promising signals in areas such as reduced blood pressure medication use and fewer orthopedic surgeries, though comprehensive multi-year studies remain limited.
Critics counter that many patients discontinue the medications after experiencing side effects or plateauing in their weight loss. Gastrointestinal issues, including nausea and vomiting, lead some users to stop treatment within months. Others regain weight once they cease injections, potentially erasing any temporary gains in related health metrics. For self-insured employers, this pattern creates a difficult forecasting challenge: initial spending spikes may not deliver proportional reductions in overall claims if adherence rates falter. Bank of America has reportedly begun tracking outcomes more closely, collecting de-identified data on employee health improvements to inform future benefit design decisions.
The pricing dynamics of these medications add another layer of complexity. Manufacturers such as Novo Nordisk and Eli Lilly have defended their list prices by citing extensive research and development investments, including large-scale clinical trials that demonstrated cardiovascular benefits. At the same time, advocacy groups and some lawmakers have questioned whether the costs reflect true innovation or simply profit maximization. Several states and large purchasers have filed legal actions or pursued bulk purchasing agreements in attempts to secure better rates. For corporations like Bank of America, these debates influence how aggressively they negotiate rebates and how transparently they communicate benefit changes to employees.
Beyond direct drug costs, the rise of GLP-1 therapies has prompted shifts in corporate wellness programming. Some employers now integrate nutritional counseling, physical activity incentives, and behavioral health support alongside medication coverage. The goal is to maximize the chances that employees achieve sustainable results rather than relying solely on pharmacological intervention. Bank of America has expanded its well-being platform to include resources tailored to members using weight management medications, recognizing that lifestyle factors remain essential even when drugs provide biological assistance.
Looking ahead, industry observers expect continued growth in GLP-1 utilization as new formulations reach the market. Oral versions currently in late-stage trials could improve convenience and potentially expand the eligible patient population. Manufacturers are also studying the drugs for additional indications, including heart failure, chronic kidney disease, and neurodegenerative conditions. Each successful label expansion could increase both medical value and budgetary impact for employers. Moynihan suggested that Bank of America will monitor these developments carefully and adjust its strategies accordingly, balancing employee needs with fiscal responsibility.
The situation at Bank of America illustrates the tension many large organizations face in the current health care environment. On one hand, providing access to effective treatments supports workforce productivity, morale, and retention. On the other, unchecked cost escalation threatens competitiveness and requires difficult trade-offs elsewhere in the benefits package. As more data accumulates on real-world outcomes, companies may gain clearer insight into which patient populations derive the greatest long-term benefit from these therapies. Until then, benefit leaders continue refining coverage policies, negotiating aggressively with suppliers, and educating employees about responsible use.
Moynihan’s comments to CNBC reflect a pragmatic stance shared by many chief executives. He acknowledged the drugs’ transformative potential for individual health while expressing concern over the aggregate expense to the company. His remarks serve as a reminder that innovation in pharmaceuticals often arrives with substantial financial implications that must be actively managed rather than passively absorbed. For Bank of America and its peers, the coming years will likely involve more sophisticated approaches to pharmacy benefits, greater emphasis on outcomes measurement, and continued dialogue with drug makers about sustainable pricing models.
As employers accumulate additional experience with GLP-1 medications, patterns around adherence, comorbidity reduction, and total cost of care should become more apparent. Those insights will shape not only Bank of America’s strategy but also the broader corporate approach to covering high-cost specialty drugs. In the meantime, the bank’s experience stands as a prominent example of how quickly popular new therapies can influence organizational budgets and why proactive management remains essential for maintaining affordable, high-quality health benefits.
Bank of America CEO: Ozempic and Wegovy Raise Health Costs 15% first appeared on Web and IT News.
